EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Gut Microbial Levodopa Metabolism and Constipation in Prodromal and Established Parkinson’s Disease

Giovanni Albani, Paolo Capodaglio iD, Marica Giardini iD, Giuseppe Modaffari, Vasuki Ranjani Chellamuthu, Yin-Xia Chao, Anusha Jayaraman iD, Salvatore Albani iD, Eng-King Tan

Nutrients · 22.10.2026 · 18 (21) · 3470

DOI: 10.3390/nu18213470 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nutrients, online erschienen am 22.10.2026. Verfasst von Giovanni Albani und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurorehabilitation of Veruno Institute, Istituti Clinici Scientifici Maugeri IRCCS, 28013 Gattico-Veruno, Italy. Hauptthemen laut MEDLINE: Parkinson Disease, Levodopa, Constipation, Gastrointestinal Microbiome. Die Arbeit nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health, Duke-NUS Medical School, SingHealth Duke-NUS Academic Medicine Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Constipation can precede the motor diagnosis of Parkinson’s disease (PD), but its mechanisms are multifactorial. Gut bacteria can metabolize administered levodopa (LD), and enteric dopamine receptors participate in the regulation of motility. These observations motivate, but do not establish, a connection between microbial LD metabolism and constipation. Evidence: Bacterial tyrosine decarboxylase (TDC) converts LD to dopamine in biochemical and animal systems. Human studies associate fecal TDC abundance with some treatment and pharmacokinetic variables, but gene abundance does not measure enzyme activity. A longitudinal PD cohort found an inverse association between constipation severity and TDC abundance in one model, highlighting the need to consider medication effects and reverse causation. Microbiome alterations in risk-enriched populations do not demonstrate increased TDC activity before PD diagnosis. Hypothesis: In a subset of untreated individuals at increased risk of PD, sufficient luminal endogenous L-DOPA might permit microbial dopamine production that influences intestinal transit, provided that the resulting dopamine reaches relevant receptors at effective concentrations. Endogenous substrate availability, anatomical access, and the net balance of dopamine production and clearance are unresolved. After LD treatment begins, a larger exogenous substrate supply creates a distinct setting for drug–microbe interactions.

Conclusions

The proposed continuum is conditional and requires biochemical and functional validation before human biomarker development. We propose substrate tracing, comparisons of TDC-positive and TDC-deficient bacteria, receptor-specific testing, and longitudinal gastrointestinal phenotyping. Current evidence does not justify TDC-directed dietary prevention of PD or clinical prediction from fecal TDC abundance alone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseLevodopaConstipationGastrointestinal MicrobiomeAntiparkinson AgentsHumansAnimalsDopamineProdromal Symptoms

Stichwörter der Autor:innen

Parkinson’s diseaseconstipationenteric dopaminenon-motor symptoms

Substanzen

LevodopaDopamineAntiparkinson Agents

Autor:innen und Institutionen

  • Division of Neurorehabilitation of Veruno Institute, Istituti Clinici Scientifici Maugeri IRCCS, 28013 Gattico-Veruno, Italy.
  • Research Laboratory in Biomechanics, Rehabilitation and Ergonomics, IRCCS, Istituto Auxologico Italiano, San Giuseppe Hospital, 28824 Piancavallo, Italy.
  • Department of Biomedical, Surgical and Dental Sciences, University of Milan, 20122 Milan, Italy.
  • Translational Immunology Institute, SingHealth/Duke-NUS Academic Medical Centre, Singapore 169856, Singapore.
  • National Neuroscience Institute, Singapore 308433, Singapore.
  • Department of Neurology, Singapore General Hospital, Singapore 169608, Singapore.

ORCID-Profile: Paolo Capodaglio, Marica Giardini, Anusha Jayaraman, Salvatore Albani

Förderung

  • Ministry of Health
  • Duke-NUS Medical School
  • SingHealth Duke-NUS Academic Medicine Research
  • A*STAR
  • Ricerca Corrente funding scheme of the Ministry of Health, Italy

Zitieren

APA

Albani, G., Capodaglio, P., Giardini, M., Modaffari, G., Ranjani Chellamuthu, V., Chao, Y. X., Jayaraman, A., Albani, S., & Tan, E. K. (2026). Gut Microbial Levodopa Metabolism and Constipation in Prodromal and Established Parkinson’s Disease. Nutrients, 18(21), 3470. https://doi.org/10.3390/nu18213470

Vancouver

Albani G, Capodaglio P, Giardini M, Modaffari G, Ranjani Chellamuthu V, Chao YX, et al. Gut Microbial Levodopa Metabolism and Constipation in Prodromal and Established Parkinson’s Disease. Nutrients. 2026;18(21):3470. doi:10.3390/nu18213470

BibTeX
@article{Albani2026,
  author = {Albani, Giovanni and Capodaglio, Paolo and Giardini, Marica and Modaffari, Giuseppe and Ranjani Chellamuthu, Vasuki and Chao, Yin-Xia and Jayaraman, Anusha and Albani, Salvatore and Tan, Eng-King},
  title = {Gut Microbial Levodopa Metabolism and Constipation in Prodromal and Established Parkinson’s Disease},
  journal = {Nutrients},
  year = {2026},
  volume = {18},
  number = {21},
  pages = {3470},
  doi = {10.3390/nu18213470}
}
Kostenlos starten →